Overview
Spherix’s coverage of the lupus nephritis market combines insights from nephrologists and rheumatologists to provide coverage on both current, as well as evolving, treatment paradigms, as patients with high unmet needs begin to see new solutions. Market trending reports coupled with patient chart audits and launch trackers for exciting new products provide unique and invaluable insights into this expanding market.
Services Available
Trending market evolution
Lupus Nephritis (US)
Exploring the patient journey
Lupus Nephritis (US)
Benchmarking new brand performance
Benlysta (GSK) and Lupkynis (Aurinia) in Lupus Nephritis (US)
Gazyva (Genentech/Roche) in Lupus Nephritis (US)*
*Pending approvals and launch
Gauging impact of disruptive events
Nephrology Biosimilars Today and Tomorrow (US)
Renal Pipeline Tracker
Feedback from ASN Conference 2022 (US)
Nephrologist Feedback on [Current Market Event] (ongoing based on industry updates)